Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study - Boys - Thoracic Cancer - Wiley Online Library
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial - ESMO Open
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors | Immunotherapy
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
The current treatment landscape in the UK for stage III NSCLC | British Journal of Cancer
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Frontiers | A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▽, AstraZeneca UK Limited) | British Journal of Cancer
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - Journal of Thoracic Oncology
WCLC 2018: PACIFIC Trial: Overall Survival With Durvalumab After Chemo-Radio therapy in Unresectable Stage III NSCLC
Blog – Page 2 – BTOG | British Thoracic Oncology Group
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) - ScienceDirect
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study - ScienceDirect
PACIFIC Trial: Adjuvant Immunotherapy Improves Overall Survival (OS) in Stage III NSCLC – BTOG | British Thoracic Oncology Group
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
Real-World Experience With Durvalumab at the Mayo Clinic Mirrors PACIFIC Trial Findings - The ASCO Post
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective | SpringerLink
![ASCO 2021] Imfinzi shows a five-year OS rate of 42.9% in stage 3 lung cancer patients - 의약뉴스](http://www.newsmp.com/news/photo/202106/215417_220095_5218.jpg "ASCO 2021] Imfinzi shows a five-year OS rate of 42.9% in stage 3 lung cancer patients - 의약뉴스")
ASCO 2021] Imfinzi shows a five-year OS rate of 42.9% in stage 3 lung cancer patients - 의약뉴스
